Finance

Roʻyxatlar
Istiqbol: 68.6% optimistik·0.0% pessimistik
Tahlilga kirish
EW:NYSE
Edwards Lifesciences Corp
104,01 US$
-0,67%
(-0,70) 1K
104,01 US$
0,00% (0,00)
Yopilgandan keyin
Savdolar yopilgan: 10-noy, 16:00:04 (GMT-5)  ·   USD
Barcha belgilar
BelgiNarxiOʻzgartirishlarDinamika (%)
EW tikeri uchun statistika yaratilmoqda...
Ochish
104,25 US$
Yuqori
104,58 US$
Past
102,43 US$
Bozor kapitali
59,81 mlrd
Oʻrtacha hajm
4,48 mln
Hajmi
3,68 mln
P/E koeffitsiyenti
58,97
52 haftalik eng yuqori
105,37 US$
52 haftalik eng past
74,66 US$
Aksiya boʻyicha daromad
1,76 US$
Beta
0,85
Muomaladagi aksiyalar
575,00 mln
Xodimlar soni
16 ming
Ochish
104,25 US$
Yuqori
104,58 US$
Past
102,43 US$
Bozor kapitali
59,81 mlrd
Oʻrtacha hajm
4,48 mln
Hajmi
3,68 mln
P/E koeffitsiyenti
58,97
52 haftalik eng yuqori
105,37 US$
52 haftalik eng past
74,66 US$
Aksiya boʻyicha daromad
1,76 US$
Beta
0,85
Muomaladagi aksiyalar
575,00 mln
Xodimlar soni
16 ming
Yangiliklar
Internet manbalari va yangilik hamkorlarimizdan
Profil
Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in tissue heart valves and transcatheter technologies for the treatment of structural heart disease. The company has manufacturing facilities at the Irvine headquarters, as well as in Draper, Utah; Costa Rica; Singapore; and Limerick, Ireland. The company is also constructing a manufacturing plant in Moncada, near Valencia, Spain, with a €150 million investment. Production is scheduled to begin in 2027. Wikipedia
Edwards Lifesciences Corp haqida
CEO-
Xodimlar soni16 ming
Asos solingan1958
Bosh ofislarIrvayn, Kaliforniya, Amerika Qo‘shma Shtatlari
SektorHealth Care
Soha-
Veb-saytedwards.com
Analitik reytinglar
Oxirgi 3 oyda EW aksiyalari boʻyicha reyting bergan 23 tahlilchi xulosasiga koʻra
Sotib olish tavsiya etiladi
Sotib olish
20
Ushlab qolish
3
Sotish
0
12 oylik prognoz
Oxirgi 3 oyda EW uchun 12 oylik narx maqsadlarini taklif qilgan 23 Wall Street tahlilchisi xulosasiga koʻra
Eng yuqori
Joriy 104,01 US$
125,00 US$ (+20,18%)
O‘rtacha
114,30 US$ (+9,89%)
Eng past
97,00 US$ (-6,74%)
Analitik
Tavsiya
Amal
Kutilayotgan narx
Prognoz
Sana
Travis Steed
Bank of America Securities
Buy
Maintained
-
-
11/09/2026
Jaret Seiberg
TD Cowen
Buy
Reiterated
117,00 US$
+12,5%
11/09/2026
Unknown Analyst
Oppenheimer
Hold
Maintained
-
-
11/05/2026
Mike Kratky
Leerink Partners
Buy
Reiterated
112,00 US$
+7,7%
11/05/2026
Anthony Petrone
Mizuho Securities
Buy
Maintained
120,00 US$
+15,4%
11/05/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
112,00 US$
+7,7%
11/05/2026
David Rescott
Robert W. Baird
Buy
Upgraded
116,00 US$
+11,5%
11/05/2026
David Roman
Goldman Sachs
Buy
Maintained
115,00 US$
+10,6%
11/05/2026
Kendall Au
RBC Capital
Buy
Reiterated
115,00 US$
+10,6%
11/05/2026
Shagun Singh Chadha
RBC Capital
Buy
Reiterated
115,00 US$
+10,6%
11/05/2026
Rick Wise
Stifel Nicolaus
Buy
Maintained
120,00 US$
+15,4%
11/05/2026
Adam Maeder
Piper Sandler
Buy
Reiterated
115,00 US$
+10,6%
11/05/2026
Robbie Marcus
J.P. Morgan
Buy
Maintained
120,00 US$
+15,4%
11/05/2026
Patrick Wood
UBS
Buy
Reiterated
118,00 US$
+13,5%
11/05/2026
Lee Hambright
Bernstein
Hold
Maintained
106,00 US$
+1,9%
11/05/2026
Larry Biegelsen
Wells Fargo
Buy
Reiterated
113,00 US$
+8,6%
11/05/2026
Joanne Wuensch
Citi
Buy
Reiterated
117,00 US$
+12,5%
11/05/2026
Nico Chen
DBS
Buy
Maintained
125,00 US$
+20,2%
11/05/2026
William Plovanic
Canaccord Genuity
Hold
Maintained
97,00 US$
-6,7%
11/05/2026
Christopher Pasquale
Barclays
Buy
Maintained
120,00 US$
+15,4%
11/05/2026
Richard Newitter
Truist Financial
Buy
Upgraded
113,00 US$
+8,6%
11/03/2026
Chris Krueger CFA
TD Cowen
Buy
Reiterated
117,00 US$
+12,5%
11/05/2026
Josh Jennings
TD Cowen
Buy
Reiterated
117,00 US$
+12,5%
11/03/2026
Marie Thibault
BTIG
Buy
Reiterated
110,00 US$
+5,8%
10/09/2026
Matt Miksic
Barclays
Buy
Maintained
110,00 US$
+5,8%
10/07/2026
Tycho Peterson
Jefferies
Buy
Initiated
110,00 US$
+5,8%
10/07/2026
Matthew Taylor
Jefferies
Buy
Maintained
105,00 US$
+1%
09/11/2026
Brandon Vazquez
William Blair
Buy
Maintained
-
-
09/10/2026
Suraj Kalia
Oppenheimer
Hold
Maintained
-
-
07/24/2026
Krish Sankar
TD Cowen
Buy
Reiterated
104,00 US$
-0%
06/02/2026
David Toung
Argus Research
Buy
Maintained
-
-
05/21/2026
Michael Polark
Wolfe Research
Buy
Upgraded
92,00 US$
-11,5%
04/01/2026
Danielle Antalffy
UBS
Hold
Maintained
90,00 US$
-13,5%
02/12/2026
Oxirgi hisobot
5-noy, 2026
Moliya davri
Ch.3 2026
0,80 US$ / 0,74 US$
+8,62%musbat
Taxminiy daromad (USD)
1,72 mlrd / 1,68 mlrd
+2,31%musbat
Q3 2026 uchun tushumlar hisoboti
Tushumlar hisoboti kutilmoqda
Qisqacha
Oxirgi yangiliklar va hisobotlar sarhisobi
Avvalgi hisobotlarBarcha qiymatlar – USD
Loading Previous Earnings...
Daromad
Sof foyda
Barcha qiymatlar – USD
dek, 2025
mar, 2026
iyn, 2026
sen, 2026
Daromad
1,57 mlrd
1,65 mlrd
1,74 mlrd
1,72 mlrd
Sotilgan mahsulotning tannarxi
343,00 mln
362,60 mln
392,40 mln
369,20 mln
Daromad narxi
343,00 mln
362,60 mln
392,40 mln
369,20 mln
Tadqiqot va ishlanmalarga xarajatlar
267,70 mln
263,30 mln
278,90 mln
281,40 mln
Tadqiqot va ishlanmalarga xarajatlar jami xarajatlar
-
-
-
-
Tijoriy, umumiy va maʼmuriy xarajatlar
601,20 mln
522,20 mln
561,20 mln
560,90 mln
Operatsion xarajatlar
854,60 mln
771,30 mln
829,10 mln
829,00 mln
Jami operatsion xarajatlar
1,20 mlrd
1,13 mlrd
1,22 mlrd
1,20 mlrd
Operatsion daromad
372,00 mln
514,70 mln
519,50 mln
517,30 mln
Boshqa nooperatsion daromad
2,30 mln
69,90 mln
-25,00 mln
25,90 mln
Soliq toʻlangunga qadar foyda, shu jumladan gʻayrioddiy moddalar
90,40 mln
459,00 mln
519,80 mln
363,20 mln
Soliq toʻlangunga qadar foyda, gʻayrioddiy moddalar bundan mustasno
464,00 mln
603,60 mln
511,10 mln
560,80 mln
Daromad soligʻi boʻyicha xarajat
26,20 mln
78,30 mln
278,40 mln
61,80 mln
Amaldagi soliq stavkasi
28,98%
17,06%
53,56%
17,02%
Boshqa operatsion xarajatlar
-14,30 mln
-14,20 mln
-11,00 mln
-13,30 mln
Sof foyda
91,20 mln
380,70 mln
241,90 mln
307,50 mln
Sof foyda marjasi
5,81%
23,09%
13,89%
17,92%
Har bir aksiya foydasi
0,58
0,78
0,78
0,80
Foizlar va investitsiyalardan olingan daromadlar
114,20 mln
17,40 mln
15,00 mln
15,90 mln
Foizlarni toʻlash xarajatlari
-20,40 mln
-
-
-
Foizlarni toʻlash boʻyicha sof xarajatlar
93,80 mln
17,40 mln
15,00 mln
15,90 mln
Amortizatsiya ajratmalari
-
-
-
-
EBITDA
414,70 mln
555,60 mln
562,20 mln
562,20 mln
Aktivlarni sotishdan olingan foyda yoki zarar
-33,90 mln
-
-
-
Insayder tranzaksiyalari
Insayder tranzaksiyalari maʼlumotlari tashqi manbalardan olingan. Batafsil
Insayder
Joylashuvi
Turi
Sana
Aksiyalar
Miqdor
1-sahifa
Kelgusi tadbirlar
AI kontentda xatolar boʻlishi mumkin. Batafsil
Google ilovalari